Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
DNTH
DNTH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DNTH News
DNTH Options Analysis: $40 Put Contract Offers Attractive Yield Boost
Jan 16 2026
NASDAQ.COM
Dianthus CFO Ryan Savitz Sells 20,000 Shares for $903,600
Jan 07 2026
Fool
Dianthus CFO Ryan Savitz Sells 20,000 Shares for $903,600
Jan 07 2026
NASDAQ.COM
Dianthus and Leads Biolabs Initiate Phase 1 Trial of LBL-047
Dec 23 2025
Globenewswire
Options Trading for Dianthus Therapeutics (DNTH) in the First Week of August 2026
Dec 19 2025
NASDAQ.COM
The Insider Report: Get Ready for the Upcoming Buying Opportunity During the Next Market Dip
Nov 23 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Dianthus Therapeutics and Increases Price Target to $47
Nov 10 2025
Benzinga
Dianthus Therapeutics Showcases New Claseprubart Findings at the 2025 AANEM Annual Meeting
Oct 29 2025
Newsfilter
"Understanding the Factors: DFUS on Track for $81"
Oct 16 2025
NASDAQ.COM
Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/17/2025
Sep 17 2025
TipRanks
Projected Target Price for XBI by Analyst: $142
Sep 15 2025
NASDAQ.COM
Significant Options Trading on Friday: GLW, DNTH, CROX
Sep 13 2025
NASDAQ.COM
Stifel Reaffirms Buy Rating for Dianthus Therapeutics and Increases Price Target to $65
Sep 12 2025
Benzinga
General Motors Set to Surge Over 24%? Check Out 10 Leading Analyst Predictions for Friday
Sep 12 2025
Benzinga
Three Biotech Stocks Demonstrating Strength with Significant Increases in Momentum Scores
Sep 12 2025
Benzinga
Dianthus Therapeutics, Inc. Completes $288 Million Public Offering with Full Exercise of Underwriters' Option for Additional Shares
Sep 11 2025
Newsfilter
Show More News
